Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists

被引：213
作者：
Mitoma, Hiroki [1 ]
Horiuchi, Takahiko [2 ]
Tsukamoto, Hiroshi [3 ]
Ueda, Naoyasu [4 ]
机构：
[1] Kyushu Univ Hosp, Dept Clin Immunol & Rheumatol Infect Dis, Fukuoka 8128582, Japan
[2] Kyushu Univ, Dept Internal Med, Beppu Hosp, Beppu, Oita 8740838, Japan
[3] Shin Kokura Hosp, Dept Internal Med, Kitakyushu, Fukuoka 8038505, Japan
[4] Miyazaki Prefectural Miyazaki Hosp, Dept Internal Med, Miyazaki 8808510, Japan
来源：
CYTOKINE | 2018年 / 101卷
关键词：
Tumor necrosis factor-alpha; Anti-TNF-alpha therapy; Inflammatory bowel disease; Rheumatoid arthritis; TUMOR-NECROSIS-FACTOR; INFLAMMATORY-BOWEL-DISEASE; REGULATORY T-CELLS; COLLAGEN-INDUCED ARTHRITIS; FC-FUSION PROTEINS; CROHNS-DISEASE; RHEUMATOID-ARTHRITIS; CERTOLIZUMAB PEGOL; TRANSMEMBRANE TNF; FACTOR RECEPTOR;
D O I：
10.1016/j.cyto.2016.08.014
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Tumor necrosis factor (TNF)-alpha is a potent pro-inflammatory and pathological cytokines in inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases. Anti-TNF-alpha therapy has been established as an efficacious therapeutic strategy in these diseases. In clinical settings, three monoclonal anti-TNF-alpha, full IgG1 antibodies infliximab, adalimumab, and golimumab, PEGylated Fab' fragment of anti-TNF-alpha antibody certolizumab pegol, extracellular domain of TNF receptor 2/IgG1-Fc fusion protein etanercept, are almost equally effective for rheumatoid arthritis. Although monoclonal full IgG1 antibodies are able to induce clinical and endoscopic remission in inflammatory bowel diseases, certolizumab pegol without Fc portion has been shown to be less effective for inflammatory bowel diseases compared to full IgG1 antibodies. In addition, there are no evidences that etanercept leads clinical remission in inflammatory bowel diseases. Besides the common effect of anti-TNF-alpha agents on neutralization of soluble TNF-alpha, each anti-TNF-alpha agent has its own distinctive pharmacological properties which cause the difference in clinical efficacies. Here we focus on the distinctions of action of anti-TNF-alpha agents especially in following points; (1) blocking ability against ligands, transmembrane TNF-alpha, and lymphotoxin, (2) effects toward transmembrane TNF-alpha-expressing cells, (3) effects toward Fc gamma receptor-expressing cells, (4) degradation and distribution in inflamed tissue. Accumulating evidence will give us the idea how to modify anti-TNF-alpha agents to enhance the clinical efficacy in inflammatory diseases. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码：56 / 63
页数：8
相关论文
共 104 条
[1]   ALVEOLAR MACROPHAGES AS A CELL SOURCE OF CYTOKINE HYPERPRODUCTION IN HIV-RELATED INTERSTITIAL LUNG-DISEASE [J].
AGOSTINI, C ;
SANCETTA, R ;
CERUTTI, A ;
SEMENZATO, G .
JOURNAL OF LEUKOCYTE BIOLOGY, 1995, 58 (05) :495-500
[2]   A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling [J].
Alexopoulou, L ;
Pasparakis, M ;
Kollias, G .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (10) :2588-2592
[3]   Anti-TNF Agents for Behcet's Disease: Analysis of Published Data on 369 Patients [J].
Arida, Aikaterini ;
Fragiadaki, Kalliopi ;
Giavri, Eirini ;
Sfikakis, Petros P. .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2011, 41 (01) :61-70
[4]   Increased expression of functionally active membrane-associated tumor necrosis factor in acute respiratory distress syndrome [J].
Armstrong, L ;
Thickett, DR ;
Christie, SJ ;
Kendall, H ;
Millar, AB .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2000, 22 (01) :68-74
[5]   Differences in binding and effector functions between classes of TNF antagonists [J].
Arora, Taruna ;
Padaki, Rupa ;
Liu, Ling ;
Hamburger, Agnes E. ;
Ellison, Aaron R. ;
Stevens, Seth R. ;
Louie, James S. ;
Kohno, Tadahiko .
CYTOKINE, 2009, 45 (02) :124-131
[6]   Antibodies Against Tumor Necrosis Factor (TNF) Induce T-Cell Apoptosis in Patients With Inflammatory Bowel Diseases via TNF Receptor 2 and Intestinal CD14+ Macrophages [J].
Atreya, Raja ;
Zimmer, Michael ;
Bartsch, Brigitte ;
Waldner, Maximilian J. ;
Atreya, Imke ;
Neumann, Helmut ;
Hildner, Kai ;
Hoffman, Arthur ;
Kiesslich, Ralf ;
Rink, Andreas D. ;
Rau, Tilman T. ;
Rose-John, Stefan ;
Kessler, Hermann ;
Schmidt, Jan ;
Neurath, Markus F. .
GASTROENTEROLOGY, 2011, 141 (06) :2026-2038
[7]  
Bedini C, 2007, BRIT J DERMATOL, V157, P249, DOI 10.1111/j.1365-2133.2007.07945.x
[8]   Proteolytic Cleavage and Loss of Function of Biologic Agents That Neutralize Tumor Necrosis Factor in the Mucosa of Patients With Inflammatory Bowel Disease [J].
Biancheri, Paolo ;
Brezski, Randall J. ;
Di Sabatino, Antonio ;
Greenplate, Allison R. ;
Soring, Keri L. ;
Corazza, Gino R. ;
Kok, Klaartje B. ;
Rovedatti, Laura ;
Vossenkaemper, Anna ;
Ahmad, Nadja ;
Snoek, Susanne A. ;
Vermeire, Severine ;
Rutgeerts, Paul ;
Jordan, Robert E. ;
MacDonald, Thomas T. .
GASTROENTEROLOGY, 2015, 149 (06) :1564-+
[9]   SOLUBLE TNF AND MEMBRANE TNF EXPRESSED ON CD4+T LYMPHOCYTES DIFFER IN THEIR ABILITY TO ACTIVATE MACROPHAGE ANTILEISHMANIAL DEFENSE [J].
BIRKLAND, TP ;
SYPEK, JP ;
WYLER, DJ .
JOURNAL OF LEUKOCYTE BIOLOGY, 1992, 51 (03) :296-299
[10]   A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells [J].
Black, RA ;
Rauch, CT ;
Kozlosky, CJ ;
Peschon, JJ ;
Slack, JL ;
Wolfson, MF ;
Castner, BJ ;
Stocking, KL ;
Reddy, P ;
Srinivasan, S ;
Nelson, N ;
Boiani, N ;
Schooley, KA ;
Gerhart, M ;
Davis, R ;
Fitzner, JN ;
Johnson, RS ;
Paxton, RJ ;
March, CJ ;
Cerretti, DP .
NATURE, 1997, 385 (6618) :729-733
12345678910